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Abstract
Introduction: Studies in mammary cancer demonstrated that moderately high concentrations of
molecular iodine (I2) have a antiproliferative and apoptotic effect either in vivo as in vitro, however
the cellular intermediated involved in these effects has not been elucidated.
Methods: Virgin Sprague-Dawley rats were treated with methyl-nitrosourea (MNU: single dose
ip, 50 mg/Kg bw) and the participation of arachidonic acid (AA) and PPAR receptors in the
antineoplasic effect of I2 where analyzed.
Results: I2-treated rats for four weeks exhibited a significant reduction in the incidence (62.5 vs.
100%) and size (0.87 ± 0.98 vs 1.96 ± 1.5 cm3) of mammary tumors. HPLC analysis showed that
tumoral but not normal mammary tissue contained an elevated basal concentration of AA and
significantly more AA-iodinated called 6-iodolactone (6-IL) after chronic I2 treatment. Tumors from
I2-treated rats showed fewer cells positive to proliferating cell nuclear antigen, lower blood vessel
density, as well as decreases in vascular endothelial growth factor, urokinase-type plasminogen
activator, and PPAR type alpha (PPARα). These same tumors showed increases in the cell death
markers, TUNEL-positive cells (p < 0.05) and the enzyme caspase-3 (trend), as well as significant
induction of PPAR type gamma (PPARγ).
Conclusion: Together, these data demonstrate that the antineoplasic effect of iodine involves 6-
IL formation and PPARγ induction.
Introduction
In recent years, it has become evident that molecular
iodine (I2) participates in the physiology and/or pathol-
ogy of extrathyroidal organs like mammary gland, stom-
ach, prostate, etc. [1-3]. In mammary gland I2 but not
iodide (I-) supplementation alleviates human mastalgia
and exerts a potent antineoplasic effect on pharmaco-
induced mammary tumoral progression in rats [4-7]. In
thyroid gland, I- has an apoptotic effect that is mediated
by derivatives of arachidonic acid (AA) or eicosapentae-
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noic acid such as 6-iodo-5-hydroxy-8,11,14-eicosa-
trienoic acid, also called 6-iodolactone (6-IL), or alpha-
iodohexadecanal, respectively [8-10]. The formation of
these iodolipids requires, in addition to iodide uptake by
specific transporters, its oxidation by thyroperoxidase
(TPO). The oxidized iodine intermediate has not been
identified, but one of the candidates is I2 [11,12]. We
reported that mammary glands of virgin rats and MNU-
induced tumors take up 125I2 by mechanisms independent
of the sodium iodine symporter (NIS) or pendrin (PEN)
[13]. These findings were corroborated in the human
tumoral cell line MCF-7, where we found that 125I2 is
taken up by a facilitated diffusion system and covalently
bound to lipids similar to 6-IL in both the presence or
absence of peroxidase inhibitors, indicating that the oxi-
dized iodine form I2 is organified in the absence of perox-
idases [14]. Our data also shows that cancerous cells are
more sensitive than the normal mammary cells to the
apoptotic effect of I2, but they are equally sensitive to 6-IL;
this suggests the presence of abundant 6-IL precursor in
tumoral cells [15]. 6-IL is formed by the iodination of AA,
which is an essential membrane lipid, and elevated AA has
been widely implicated in tumoral process [16,17].
Although the cellular mechanism involved in the 6-IL
apoptotic effect has not yet been elucidated, we have pro-
posed that the peroxisome proliferator-activated receptors
(PPAR) could be the mediator [3]. These ligand-depend-
ent transcription factors are involved in regulating cell
cycle control and apoptosis of several cancer cells [18,19].
Recently, our laboratory showed that 6-IL is a specific lig-
and of PPARs with almost 6-fold higher affinity than AA,
which is one of the endogenous ligands of these receptors
[20]. In the present work we analysed, in an in vivo model,
the presence of AA and formation of its 6-IL derivative in
normal and tumoral mammary gland after chronic sup-
plement of I2. We also characterized the cellular pathways
involved in the antineoplasic effect of I2 treatment.
Our data show that tumoral tissue contains 5-fold more
AA and produce 12 times more 6-IL than normal mam-
mary tissue, and that this increase in 6-IL is accompanied
by decreases in invasive signals as well as increases in
apoptosis indicators. In normal mammary gland from I2-
treated rats, these parameters have not shown any changes
compared to untreated rats. Together, these data demon-
strated that the antineoplasic effect of iodine involves the
formation of 6-IL and PPARγ induction.
Materials and methods
Animals
Virgin, female Sprague-Dawley rats, 5 weeks of age, were
obtained from the vivarium of the Instituto de Neuro-
biología, UNAM-Juriquilla. Rats were housed in a temper-
ature-controlled room (21 ± 1°C) with a 12-h light/dark
schedule. They were provided with food (Purina rat chow;
Ralston Purina Co., St. Louis, Missouri, USA) and water ad
libitum. All of the procedures followed UNAM Animal
Care and Use Committee guidelines.
Iodine treatment and carcinogenesis induction
At 5 weeks old, rats were sorted into 2 experimental
groups using a randomization process, and iodine treat-
ment was started. The experimental groups were: a) Con-
trol and b) 0.05% I2 in drinking water (I2). Distilled water
was used for drinking water and for all solutions. A satu-
rating solution of I2 (1.33 × 10-3 M) was prepared, and the
concentration of 0.05% was confirmed by titration with
sodium thiosulfate (Kenkel, 1994). Treatments were con-
tinued until 16 weeks after carcinogen injection. Two
weeks after the I2 treatment began, subgroups of rats (con-
trol and I2 treatment) were anesthetized with a mixture of
ketamine and xylazine (Cheminova, México, 30 mg and 6
mg, respectively, per Kg bw) and given a single intraperi-
toneal injection of 50 mg of MNU (Sigma, St. Louis, Mis-
souri, USA) per Kg bw. MNU was dissolved and activated
by heating to 50–60°C in 0.9% saline, pH 5.0 [21].
Evaluation of mammary gland carcinogenesis
Rats were weighed and palpated for tumors every week
beginning 4 weeks after and ending 16 weeks after MNU
administration. A tumor was defined as a discrete, palpa-
ble mass recorded for at least 2 consecutive weeks. Tumor
incidence was calculated as the percentage of animals with
one or more palpable tumors. Tumor multiplicity was cal-
culated as the average number of tumors per animal in
each treatment group. The mean latency of tumor onset
for each treatment group was calculated as the mean time
interval (in weeks) from MNU injection to the appearance
of the first palpable tumor. At the end of the experiment
the rats from each group were sacrificed by decapitation.
Tumor sizes were measured using a caliper, and the vol-
umes were calculated by the ellipsoid formula [21]. If the
tumors reached the ethically maximal size of 3 cm3 (1.5 ×
2.0 cm), rats were anesthetized with the ketamine/xyla-
zine mixture, and the tumors were surgically removed
even before the end of the experiment. Normal or tumoral
mammary glands were fixed in 10% neutral buffered for-
malin or frozen in dry ice and kept at -70°C. Blood was
collected to determine T3 circulating levels.
T3 circulating levels
Serum T3 levels were measured by the homologous RIA
method previously described [7].
Histopathological analysis
Fixed mammary tumors were embedded in paraffin
blocks. Sections of 5-μm thickness were cut from each
block and placed on slides that had been treated with 3-
aminopropyltriethoxysilane. Sections were deparaffinized
in xylene, rehydrated in descending grades of ethanol, andMolecular Cancer 2009, 8:33 http://www.molecular-cancer.com/content/8/1/33
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stained with hematoxylin and eosin. Tumors were classi-
fied according to criteria published by Russo & Russo [22].
Arachidonic acid (AA) and 6-iodolactone (6-IL) 
identification
Normal and tumoral mammary tissues were collected and
stored frozen; 500 mg tissue samples were used for neutral
lipid extraction according to the procedure described by
Boeynaems and Hubbard (1980), and the extracts were
evaporated to dryness under a stream of N2 and stored at
-80°C. Before HPLC (BIO-RAD 2800, Hercules Califor-
nia, USA) analysis, the neutral lipids were dissolved in
100% EtOH, and a standard curve was constructed with
10–500 nmol of pure AA (Amershan, Arlington Heights,
Illinois, USA) or 6-IL dissolved in ethanol. The samples
(100 μl) were injected into the μBondapak C18 column
(3.9 × 300 mm; particle size, 10 μm; WATERS, Milford,
Mississippi, USA) maintained at room temperature. Elu-
tion was performed with a mobile phase gradient using
solution A (CH3CN-H2O; 1:2, vol/vol) and solution B
(CH3CN-H2O; 2:1, vol/vol) at 1 ml/min. Absorption was
measured at 206 nm.
Immunohistochemistry of proliferating cell nuclear antigen 
(PCNA)
Five-μm sections of mammary tumors from rats with or
without I2 treatment were deparaffinized, rehydrated, and
subjected to antigen retrieval (10 mM sodium citrate) at
80°C for 20 minutes. After cooling at room temperature,
sections were treated with 0.3% hydrogen peroxide to
block endogenous peroxidase activity. Non-specific bind-
ing was blocked with 2% dried fat-free milk in 20% fetal
bovine serum-PBS solution (1 hr at 37°C). Sections were
incubated at room temperature for 30 min in a humid
chamber with mouse monoclonal anti-rat PCNA, clone
PC10 (DakoCytomation, Carpinteria, California, USA),
diluted 1:150. Immunocomplexes were visualized by goat
anti-mouse-immunoglobulin, peroxidase labeled (EnVi-
sion™+System, peroxidase, DakoCytomation, Carpinteria,
California, USA). Diaminobenzidine (DAB) was used as
the chromogen to generate a brown precipitate after reac-
tion with peroxidase. Sections were counterstained with
hematoxylin, rinsed, dehydrated, and mounted with
Entellan (Merk, Darmstadt, Germany). Cells expressing
the antigen were identified by a brown stain over the
nucleus. Tumor sections were incubated without either
the primary or secondary antibody to test for the specifi-
city of the antibody. PCNA-positive cells were identified
by a brown stain over the nucleus. Labeling indices were
obtained by counting the number of labeled cells among
at least 500 cells per region, and 5 random regions were
analyzed.
Quantification of blood vessels
The protocol described was used to prepare the sections
for immunofluorescence. Blood vessels were marked
using the anti-mouse antibody coupled to fluorescein iso-
thiocyanate (Alexa Fluor 488; Molecular Probes, Eugene,
OR). This antibody stained blood vessels in all samples, as
confirmed by dual label immunofluorescence studies
with anti-PECAM-1 [23], and the number of stained
blood vessels was determined visually (5 areas per slide)
with a 10× objective. Images were digitized and evaluated
with image-analysis software. Blood vessels were out-
lined, and their areas were calculated.
Quantification of in situ cell death
Cell death was detected in formalin-fixed, paraffin-
embedded tumor sections using the in situ cell death
detection kit, fluorescein, POD (Roche Molecular Bio-
chemicals, Mannheim, Germany), which is based on the
terminal deoxynucleotidyl transferase-mediated dUTP
nick end labeling (TUNEL) method. Sections (5 μm) were
prepared and treated according to the manufacturer's
instructions. DAB was used as the chromogen, and sec-
tions were counterstained with hematoxylin. TUNEL-pos-
itive cells were identified by a brown stain over the
nucleus. Five regions, chosen at random, were analyzed,
and labeling indices were obtained by counting the
number of labeled cells among at least 500 cells per region
and expressed as percentage values.
Caspase-3 activity
Caspase-3 activity was measured using a standard colori-
metric kit (Sigma, St. Louis, MO). Briefly, frozen mam-
mary tumors were homogenized (1:2) with lysis buffer
(50 mM HEPES, pH 7.4, 5 mM CHAPS, 5 mM DTT, 4°C).
Samples were centrifuged at 16, 000 g for 20 min, 4°C,
and supernatants were collected and stored at -70°C. Pro-
tein concentrations were determined by the Bradford
method (BIO-RAD protein assay, Richmond, CA), and
100 μg of protein were assayed for caspase activity. The
substrate was 200 μM DEVD-pNa, which contains the
chromophore p-nitroanilide (pNa) linked to a synthetic
tetrapeptide DEVD (acetyl-Asp-Glu-Val-Asp). Final cock-
tail (300 uL) were incubated in assay buffer (20 mM
HEPES, pH 7.4, 2 mM EDTA, 0.01% CHAPS, 5 mM DTT)
for 3 h at 37°C with continuous agitation and protected
from light in a 96-well plate. Samples were read at 405 nm
in an ELISA reader, and caspase activity was expressed as
nmol of pNa released/h/mg protein.
Expression of vascular endothelial growth factor (VEGF), 
urokinase-type plasminogen activator (uPA), and PPAR 
receptors
VEGF, uPA, and the alpha and gamma PPAR receptor iso-
forms were quantified by quantitative real-time PCR
(qPCR). Total RNA from normal and tumoral mammary
gland from rats with or without I2 treatment was extracted
using TRIzol reagent (Life technologies, Inc) according to
the manufacturer's instructions. Two micrograms of total
RNA was reversed transcribed using the Superscript II sys-Molecular Cancer 2009, 8:33 http://www.molecular-cancer.com/content/8/1/33
Page 4 of 9
(page number not for citation purposes)
tem (Invitrogen, Carlsbad, CA). PCR was performed on
the sequence detector system Roto-Gene 3000 (Corbett
Research, Mortlake, NSW) using SYBR green as a marker
for DNA amplification. The reaction was performed with
1 μL cDNA template and the qPCR supermix-UDG kit
(Invitrogen), using 40 cycles of three-step amplification
(94°C for 30 s, 55–58°C for 30 s, 72°C for 30 s) and the
gene-specific primers listed in Table 1. PCR generated
only the expected specific amplicon, which was demon-
strated in each case by the melting temperature profile
(dissociation curve) and by electrophoresis of 5 μL of the
PCR product through a 2% agarose gel containing ethid-
ium bromide in TAE buffer. No PCR products were
observed in the absence of template. Gene expression was
calculated using the Dcycle threshold (Dct) method and
normalized to the content of Cyclophilin (Cyc), a non-
regulated housekeeping gene [13]. All measurements were
performed in triplicate.
Statistical analysis
The effects of dietary treatments on mammary cancer inci-
dence were analyzed using 2 × 2 contingency tables and a
one-tail chi-square with Yates' correction test. The effects
of treatments on tumor multiplicity, tumor latency, tumor
size, caspase-3 activity, PCNA, TUNEL, and vascular area
counts were analyzed using the unpaired t test; for the
other variables, two-way ANOVA analysis was performed
to determine the significance of differences between
groups, followed by Tukey's test for the significance of dif-
ferences among multiple experimental groups. Values
with p < 0.05 were considered statistically significant.
Results
Mammary glands were evaluated both macro- and micro-
scopically for the presence of tumors. Various combina-
tions of papillary, cribriform, or comedo mammary
carcinomas were detected, and no correlation between
histological type of mammary cancer and treatment was
observed (data not shown). The effect of long-term I2
treatment on mammary carcinogenesis is summarized in
Table 2. Cancer incidence was 37.5% lower in I2-treated
than in control rats, whereas the number of tumors per rat
and latency were similar for all groups. As shown in the
table 3, body weight and thyroid status remained similar
in all groups.
Our first objective was to determine the concentrations of
AA and 6-IL in normal and tumoral mammary tissue with
and without I2  treatment. As shown in the figure 1,
tumoral tissue contains 5-fold more AA than normal
mammary gland, and after the I2 treatment, both normal
and tumoral tissue contain detectable 6-IL; however, the
concentration in tumoral tissue is 12 times greater than in
the control.
Figure 2 shows the analysis for cell proliferation in mam-
mary tumors of control and I2-treated rats. Tumors of con-
trol rats had significantly more PCNA-positive epithelial
cells than tumors of I2-treated rats (250 ± 51 vs 173 ± 46
positive cells/500 cells) p < 0.05%. Moreover, mammary
tumors of I2-treated rats were smaller than those of con-
trols (0.87 ± 0.98 vs. 1.96 ± 1.5 cm3, p < 0.05%).
To evaluate the effect of I2 treatment on cell death, we used
the TUNEL method. Figure 3 shows representative tumor
sections of control and I2-treated tumors. Interestingly,
mammary tumors of I2-treated rats showed specific zones
with numerous TUNEL-positive cells, whereas control
tumors have few and disperse TUNEL-positive cells. The
mammary tumors of I2-treated rats had a much higher
percentage of TUNEL-positive cells (15 ± 5.5%) than the
control tumors (1.0 ± 1.1%).
To clarify if the cell death induced by I2 is apoptosis, we
measured the activity of the enzyme caspase-3 (figure 4).
We found a tendency toward higher caspase-3 activity (p
= 0.246) in I2-treated tumors than in control tumors.
To evaluate the effect of iodine on tumoral angiogenesis
and invasive potential, we analysed the vasculature area
and the expression of VEGF, as well the expression of uPA,
respectively. Figures 5, 6, and 7 show that tumors from I2-
treated rats exhibited significant decreases in vasculature
area as well as lower expression of VEGF and uPA mRNA.
They also show that in normal mammary tissue the I2
treatment does not induce any changes in VEGF expres-
sion (figure 6) and that uPA expression remains undetec-
table (figure 7).
The last objective of this study was to analyze the partici-
pation of PPAR receptors in the antineoplastic effect of
iodine. Figure 8 shows in first time that untreated mam-
mary tumors express significantly higher levels of PPARα
and significantly lower levels of PPARγ than normal mam-
mary gland. The second find is that I2 treatment exerts a
significant decrease in the expression of PPARα and a sig-
Table 1: Oligonucleotides
PPAR-α M88529 tgtatgaagccatcttcacg ggcattgaacttcatagcga 163
PPAR-γ AF156665 tcaaaccctttaccacggtt caggctctactttgatcgca 147
β-actin NM-031144 gtcccagtatgcctctggtcgtac ccacgctcggtcaggatcttcatg 171
VEGF Nakamura et al, 1996 gctctcttgggtgcactgga caccgccttggcttgtcaca 563
431
uPA gtggccaaaagactctgagg caagcgtgtcagcgctgtag 267Molecular Cancer 2009, 8:33 http://www.molecular-cancer.com/content/8/1/33
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nificant increase of the PPARγ isoform in comparison
with control tumors. In normal mammary gland; I2 treat-
ment does not modify the expression of either of these
receptors.
Discussion
This report confirms our previous observations that I2
treatment reduces mammary cancer incidence [7],
decreases the proliferative rate (PCNA), and induces
apoptosis (TUNEL and caspases) in cancerous mammary
cells in vitro [14,15] or in vivo without any secondary
adverse effect on the thyroid or general health [13]. One
interesting effect of I2 treatment observed in these tumors
was the generalized reduction in proliferation and vascu-
lature, but the regionalized zones with positive apoptotic
signaling (TUNEL) suggest the existence of cell popula-
tions with differential I2-sensitivity Although we cannot
yet explain this pattern, it is well known that tumors are
heterogeneous populations of cells. Studies in our labora-
tory [15] have shown that cancer cells – either differenti-
ated or not – are more susceptible to the apoptotic effect
of I2 than the corresponding normal mammary epithe-
lium (MCF-7 > MDA-MB231 > MCF-12F cells lines,
respectively). Indeed, this characteristic pattern of apop-
totic zones could account for the lack of significant differ-
ences in caspase-3 activity, since it was measured in
homogenized pieces of tumors; it may also account for
our previous observation that tumor growth resumes if I2
treatment is suspended. [7]. The specific components
involved in this I2-sensitivity are not known; however the
content of lipids that can be iodinated is an attractive pos-
sibility.
The present work demonstrates that tumoral tissue con-
tains significantly higher concentrations of arachidonic
acid than normal mammary tissue and that the I2 treat-
ment is accompanied by a 12-fold increase in 6-IL forma-
tion. These findings support our earlier hypothesis that
the antiproliferative effect of I2 is mediated by the forma-
tion of the 6-IL [3]. In thyroid, the apoptotic effect of
iodine excess is mediated by 6-IL and/or by iodohexade-
canal, both of which are generated by the oxidation and
organification of I- by TPO [9,10]. In this regard, we
reported that in thyroid, excess I2 exerts, as I-, an inhibitory
effect on NIS, PEN, TPO, and deiodinase type 1 expres-
sion, but without the transient decline in circulating thy-
roid hormone (TH) levels. This finding indicates that I2
can bind to organic components and thereby inhibit gene
expression and also generate TH. Moreover, the finding
that I2-treated animals supplemented with methimazole
preserve the thyroid gene expression pattern of the Wolf-
Chaikoff effect supports the proposals that I2, as an oxi-
dized form of iodine does not need TPO for its organifica-
Table 2: Effect of long-term I2-treatment on mammary tumorigenesis after 16 weeks of MNU administration.
Treatment No. of rats with tumors % Tumor latency (weeks)† Tumors per rat†
MNU 10/10 100 11.9 ± 2.8 2.5 ± 1.7
I2-MNU 10/16* 62.5* 11.6 ± 1.4 2.0 ± 0.9
At 5 weeks of age, rats were treated with 0.05% I2 in the drinking water. Two weeks later, rats received a single i.p. injection of MNU (50 mg/Kg 
bw), and the administration of I2 was continued until 16 weeks had elapsed. † indicates mean ± SD. Asterisk (*) indicates P < 0.05 compared to 
MNU.
Table 3: Body weight gain and T3 levels after 16 weeks of iodine 
treatment.
Treatment Body weight gain (g) T3 (ng/dl)
Control 154 ± 15 63.7 ± 10
MNU 157 ± 12 67.9 ± 3
Control + I2 152 ± 9 63.2 ± 11
MNU + I2 150 ± 16 60.2 ± 5.6
Chromatographic analyzes Figure 1
Chromatographic analyzes. Quantification by HPLC of 
arachidonic acid (AA) content and 6-iodolactone (6-IL) for-
mation in normal (MG) or tumoral (Tumor) mammary glands 
from rats with or without molecular iodine supplements. A, 
representative chromatograms; a) base line, b) standards, c) 
MG control, d) MG +I2, e) tumor, f) tumor + I2. B, quantifica-
tion; data are expressed as the mean ± SD (n = 10). Differ-
ences between experimental groups were analyzed using a 
one-way ANOVA and the Tukey-HSD Test. *indicates signif-
icant difference from the appropriate control (p < 0.05)Molecular Cancer 2009, 8:33 http://www.molecular-cancer.com/content/8/1/33
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Proliferative rate Figure 2
Proliferative rate. Immunohistochemical presence of 
PCNA-positive cells in tumors from control (A) and I2-sup-
plemented rats (B); PCNA-positive cells were revealed with 
diaminobenzidine (brown stain) and counterstained with 
hematoxylin (purple stain). C, quantification; D, size of 
tumors (Volume). Differences between experimental groups 
were analyzed using an unpaired t test. *indicates significant 
difference from the appropriate control (p < 0.05).
Apoptotic rate Figure 3
Apoptotic rate. Representative sections of TUNEL-posi-
tive cells in tumors from control (A) or I2-treated rats (B), 
magnification 20×. C, Section of rat tumor treated with I2 
that shows an extensive zone of TUNEL-positive cells (white 
arrows), magnification 10×. TUNEL-positive cells were 
revealed with diaminobenzidine (brown stain) and counter-
stained with hematoxylin (purple stain). D, TUNEL-positive 
cell quantification. The difference between experimental 
groups was analyzed using an unpaired t test. *indicates sig-
nificant difference from the control (p < 0.05)
Caspase-3 activity Figure 4
Caspase-3 activity. Individual tumors from control or I2-
treated rats were assayed; horizontal line represents the 
mean of each group. Differences between experimental 
groups were analyzed using an unpaired t test. A tendency 
toward higher caspase-3 activity (p = 0.246) in I2-treated 
tumors was observed.
Vascular area Figure 5
Vascular area. Immunofluorescence blood vessels in 
tumors from control (A) and I2-supplemented rats (B). Vessel 
area was calculated as the total field area positively stained 
for the vascular marker (μm2). C, quantification. Differences 
between experimental groups were analyzed using an 
unpaired t test. *indicates significant difference from the con-
trol (p < 0.05)Molecular Cancer 2009, 8:33 http://www.molecular-cancer.com/content/8/1/33
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tion and that a putative iodine-containing organic
compound that mediates these effects is generated [13].
These findings agree with previous data obtained in the
MCF-7 cell line, where we found that 125I2 is taken up by
a facilitated mechanism and that iodinated lipids with a
migration similar to that of 6-IL are formed in a process
that is not blocked by propylthiouracil (PTU) [14]. It is
also interesting that 6-IL is present in I2-treated normal
mammary glands, and the possibility that 6-IL at this con-
centration (0.13 nmol/g) could exert functional effects
cannot be dismissed. An analysis investigating this is cur-
rently under progress.
Our present data show that I2  treatment significantly
reduces PPARα and increases PPARγ expression, findings
that could explain the antineoplasic effect of I2. It is well
documented that in mammary cancer cells PPARα is over-
expressed, and its activation correlates with proliferation
[19,24]. In contrast, in the rat MNU-mammary cancer
model dietary treatment with GW7845, an agonist of
PPARγ, significantly reduced tumor incidence, tumor
number, and tumor weight [25]. Moreover, the significant
decrease in vasculature, as well as in VEGF and uPA
expression observed in tumors from I2-treated rats, is
additional evidence that PPAR receptors participate in the
antineoplasic effect of I2. In fact, it has been reported that
VEGF is upregulated by PPARα agonists [24,26], whereas
uPA is inhibited by PPARγ activation [27]. VEGF is a
potent mitogen with high specificity for endothelia, and it
undergoes alternative splicing generating several isoforms
[28]. We showed that isoforms 120 and 164, which are
the most involved in angiogenesis, are present in MNU-
induced tumors and that I2  treatment decreased the
expression of both in a similar manner. The inhibition of
PPARα expression might explain this effect, although
more complex mechanisms could also be involved. Estro-
gen is known to induce VEGF expression [29], and
recently it was reported that iodine inhibits the expression
of several estrogen-responsive genes in MCF-7 cells [30].
Although the detailed mechanism involved in this effect
has not been elucidated, PPARγ was shown to exert an
inhibitory effect on estrogen-responsive genes via cross-
talk with the estrogen receptor binding sites [31]. On the
other hand, uPA is a 53-kDa trypsin-like protease that
converts the zymogen plasminogen into active plasmin.
Although uPA is a relatively specific protease, plasmin acts
on a wide variety of protein substrates including metal
proteases that destroy the extra cellular matrix (ECM), the
degradation of which is a prerequisite for cancer invasion
and metastasis [32]. uPA has been used as a specific
Vascular Endothelial Growth Factor (VEGF) expression Figure 6
Vascular Endothelial Growth Factor (VEGF) expres-
sion. Isoforms of VEGF mRNA in normal (MG) or tumoral 
(tumor) mammary glands from control or I2-treated rats 
were measured by the real time PCR method. A. Represent-
ative gel of amplicon of Cyclophilin (Cyc) and 120 and 164 
isoforms of VEGF mRNA in 2% agarose gel stained with 
ethidium bromide. 1, ladder; 2, MG; 3, MG + I2., 4, Tumor; 5, 
Tumor + I2; 6, all the PCR reagents without RT sample. B. 
VEGF mRNA quantification. Cyclophilin (Cyc) served as 
internal control and was used to normalize for differences in 
input RNA. Data are expressed as the mean ± SD. Differ-
ences between experimental groups were analyzed using a 
one-way ANOVA and the Tukey-HSD Test. Means with dif-
ferent letters are significantly different (p < 0.05)
Urokinase Plasminogen Activator (uPA) expression Figure 7
Urokinase Plasminogen Activator (uPA) expression. 
uPA mRNA in normal (MG) or tumoral (tumor) mammary 
glands from control or I2-treated rats were measured by the 
real time PCR method, and Cyclophilin (Cyc) served as inter-
nal control. UD, undetectable levels. Data are expressed as 
the mean ± SD. Differences between experimental groups 
were analyzed using a one-way ANOVA and the Tukey-HSD 
Test. Means with different letters are significantly different (p 
< 0.05)Molecular Cancer 2009, 8:33 http://www.molecular-cancer.com/content/8/1/33
Page 8 of 9
(page number not for citation purposes)
marker for invasiveness in mammary cancer pathology.
The presence of high concentrations of uPA in primary
breast cancers correlates with a poor prognosis [33]. I2,
after its conversion to 6-IL could, on the one hand, trigger
the apoptotic cascades and on the other, decrease the
invasive potential of cancer cells by inhibiting the expres-
sion of metastatic components like VEGF and uPA, which
would account for the antineoplastic effect of I2.
In conclusion, these data support our notion that I2 sup-
plement could be an adjuvant in the therapy of mammary
cancer, where the high concentration of AA characteristic
of tumoral cells serves as substrate to form 6-IL, which in
turn triggers the activation of apoptotic and anti-invasive
pathways by modulating PPAR receptors.
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